oral, selective PKC_ kinase inhibitor

Ph. I candidate for Psoriasis

from screen of internal library and SBDD

Journal of Medicinal Chemistry

Celgene/BMS, San Diego, CA, USA


The Celgene/BMS PKCθ kinase inhibitor, CC-90005, highlighted by Julien Lefranc, is a clinical candidate in Ph. I for psoriasis, with some dosing being conducted in healthy volunteers. The safety profile is…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: